Abstract: OBJECTIVE To explore the correlation of warfarin clinical reference factors and genetic factors and warfarin stable maintenance dose, and try to construct a predictive model for the stable maintenance dose of warfarin in patients with non valvular non-valvular-disease atrial fibrillation (NVAF). METHODS The genetic polymorphisms of cytochrome P450 2C9 and vitamin K epoxide reductase were detected in 126 patients who were selected according to the inclusion criteria, using the sequencing reaction general kit and fluorescence detector. The clinical reference factors of warfarin were recorded at the same time:age, body mass, atrial fibrillation risk scoring system (CHA₂DS₂-VASc) score, atrial fibrillation risk score system (HAS-BLED) score, glutamic-pyruvic transaminase (ALT), glomerular filtration rate (GFR), left ventricular ejection fraction (LVEF), mitral valve ring left ventricular wall tissue doppler S. The correlation analysis was used to investigate the correlation between the clinical reference factors and the stable maintenance dose of warfarin. The warfarin stable maintenance dose prediction model was established by multiple linear regression. RESULTS The study showed that body mass, level of ALT, mitral valve ring left ventricular wall tissue doppler S were positively correlated with the stable maintenance dose of warfarin, while the age, CHA₂DS₂-VASc score, HAS-BLED score were were negatively correlated, while LVEF and GFR did not show significant correlation. The accuracy rate of the existing samples was 55.6%. CONCLUSION The model can be used to predict the stable maintenance dose of warfarin in NVAF patients.